Breaking News
Sort by:
Top Post
Almirall Appoints Mercedes Diz as VP, Corporate Strategy
Almirall, a global biopharmaceutical company focused on skin health, today announced that Mercedes Diz will […]
DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and myeloid […]
Mauna Kea Technologies Announces the Appointment of Côme de La Tour du Pin as its Chief Financial Officer
Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) […]
DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer
DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small […]
Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer
Reata Pharmaceuticals, a global biopharmaceutical company focused on developing and commercializing novel therapies for patients […]
Akumin Appoints President and Chief Operating Officer
Akumin, a national partner of choice for U.S. hospitals, health systems and physician groups, with […]
Genezen Announces the Appointment of Key Executive Leaders, Expanding Viral Vector Capabilities
Genezen, a gene and cell therapy contract development and manufacturing organization (CDMO), today announced the […]
Sir Richard Roberts Elected to National Academy of Sciences
New England Biolabs (NEB®) has announced that Sir Richard Roberts, Nobel Prize winner and Chief […]
EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer
EpimAb Biotherapeutics, a clinical-stage biotechnology company specializing in the development of bispecific antibodies, today announced […]
Amarna Therapeutics Announces Appointment of Dr. Henk Streefkerk as New CEO
Amarna Therapeutics, a privately-held biotechnology company developing transformative gene therapies in a range of rare […]
XNK Therapeutics Appoints Hugo Petit as Chief Financial Officer
XNK Therapeutics today announced the appointment of Hugo Petit as Chief Financial Officer (CFO) and […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more